DARZALEX 100 mg/5mL
Daratumumab · INJECTION, SOLUTION, CONCENTRATE · Janssen Biotech, Inc.
No Recall History
Plain English
DARZALEX is a injection, solution, concentrate containing daratumumab at 100 mg/5mL, taken intravenous. Manufactured by Janssen Biotech, Inc..
Key Facts
- Brand Name
- DARZALEX
- Generic Name
- Daratumumab
- NDC Code (Product)
57894-502- Manufacturer
- Janssen Biotech, Inc.
- Strength
- 100 mg/5mL
- Dosage Form
- INJECTION, SOLUTION, CONCENTRATE
- Route
- INTRAVENOUS
- Marketing Status
- Application #
- BLA761036
- Drug Class
- CD38-directed Cytolytic Antibody [EPC]
- Marketing Start
- 11/16/2015
Recall History
No Recall HistoryFrequently Asked Questions
What is DARZALEX used for?
DARZALEX contains Daratumumab. It is a injection, solution, concentrate taken intravenous. Consult your doctor for specific uses.
Is DARZALEX a controlled substance?
DARZALEX is not classified as a controlled substance by the DEA.
What is the generic name for DARZALEX?
The generic name for DARZALEX is Daratumumab. There are 2 other brand versions of Daratumumab.
What is the NDC code for DARZALEX 100 mg/5mL?
The NDC (National Drug Code) for DARZALEX 100 mg/5mL is 57894-502, listed by Janssen Biotech, Inc..